Antioxidant agent-8, an orally active compound, inhibits Aβ 1-42 deposition by preventing fibril aggregation (IC 50 = 11.15 µM) and aiding in fibril disaggregation (IC 50 = 6.87 µM). It counteracts Cu2+-induced Aβ 1-42 fibril aggregation and disaggregation with lower IC 50 values of 3.69 µM and 3.35 µM, respectively. Additionally, it exhibits antioxidant and anti-inflammatory activities, demonstrates biosafety and blood-brain barrier permeability, and provides a neuroprotective effect.